Pubblicazioni

Impact of donor-derived CD34+infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT

2022 - BONE MARROW TRANSPLANTATION

Czerw, T; Iacobelli, S; Malpassuti, V; Koster, L; Kroger, N; Robin, M; Maertens, J; Chevallier, P; Watz, E; Poire, X; Snowden, Ja; Kuball, J; Kinsella, F; Blaise, D; Remenyi, P; Mear, Jb; Cammenga, J; Rubio, Mt; Maury, S; Daguindau, E; Finnegan, D; Hayden, P; Hernandez-Boluda, Jc; Mclornan, D; Yakoub-Agha, I

Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP

2022 - BONE MARROW TRANSPLANTATION

Onida, F; Sbianchi, G; Radujkovic, A; Sockel, K; Kroger, N; Sierra, J; Socie, G; Cornelissen, J; Poire, X; Raida, L; Bourhis, Jh; Finke, J; Passweg, J; Salmenniemi, U; Schouten, Hc; Beguin, Y; Martin, S; Deconinck, E; Ganser, A; Zver, S; Lioure, B; Rohini, R; Koster, L; Hayden, P; Iacobelli, S; Robin, M; Yakoub-Agha, I

Outcomes and toxicity of allogeneic HCT in CML patients previously treated with second generation TKIs: a prospective non-interventional study from the Chronic Malignancy Working Party of EBMT

2022 - BONE MARROW TRANSPLANTATION

Masouridi-Levrat, S; Olavarria, E; Iacobelli, S; Aljurf, Md; Morozova, E; Niittyvuopio, R; Sengeloev, H; Remenyi, P; Helbig, G; Browne, P; Ganser, A; Nagler, A; Snowden, J; Robin, M; Passweg, J; Van Gorkom, G; Labussiere, H; Hoek, J; van Biezen, A; de Witte, T; Kroger, N; Hayden, P; Chalandon, Y; Yakoub-Agha, I